Eli Lilly and Company (NYSE: LLY) today announced that it expects 2024 full-year worldwide revenue to be approximately $45.0 ...

Drug major Eli Lilly and Co. (LLY) on Tuesday trimmed its fourth-quarter revenue view below the Street estimates, but raised forecast ...

Eli Lilly expects 2024 revenue of $45.0 billion, reflecting a 32% increase, with strong contributions from Mounjaro and ...

While the U.S. incretin market grew 45% compared to the same quarter last year, our previous guidance had anticipated even faster acceleration ...

Samford University received a $5 million grant from an out-of-state philanthropy foundation, marking the school’s largest ...

But, no matter what direction the general market takes, some stocks could stand out, potentially in 2025, and most ...

Eli Lilly and Company (NYSE:LLY) 43rd Annual J.P. Morgan Healthcare Conference January 14, 2025 5:15 PM ETCompany ParticipantsDave Ricks - Chairman ...

Asian shares are mixed after gains for oil and gas producers helped offset drops for Nvidia and other Big Tech companies on ...

Eli Lilly (LLY) shares traded down more than 6% Tuesday after the company reported revenue guidance for the fourth quarter of ...

Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street ...

The phrase Make America Great Again doesn’t have to divide us. Let’s reframe it as a challenge to rise to our potential — a call to make Indiana and America a better place for everyone, regardless of ...

Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics?